Gene · 580
Papers4,139
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,081 to 1,100 of 4,139
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| BRCA-Mutated Pancreatic Cancer: From Discovery to Novel Treatment Paradigms. | Cancers (Basel) | 2022 | 35626055 | PubTator, text mining | PubMed |
| Clinical Impact of Pathogenic Variants in DNA Damage Repair Genes beyond BRCA1 and BRCA2 in Breast and Ovarian Cancer Patients. | Cancers (Basel) | 2022 | 35626031 | PubTator, text mining | PubMed |
| Whole-Exome Sequencing of Germline Variants in Non-BRCA Families with Hereditary Breast Cancer. | Biomedicines | 2022 | 35625741 | PubTator, text mining | PubMed |
| Further refining 2020 ESGO/ESTRO/ESP molecular risk classes in patients with early-stage endometrial cancer: A propensity score-matched analysis. | Cancer | 2022 | 35617463 | PubTator, text mining | PubMed |
| Cancer Risk C (CR-C), a functional genomics test is a sensitive and rapid test for germline mismatch repair deficiency. | Genet Med | 2022 | 35616648 | PubTator, text mining | PubMed |
| miR-3942-3p Increases the radiosensitivity of nasopharyngeal carcinoma through negatively regulating BARD1. | Acta Biochim Pol | 2022 | 35616619 | PubTator, text mining | PubMed |
| The structure-function analysis of Obg-like GTPase proteins along the evolutionary tree from bacteria to humans. | Genes Cells | 2022 | 35610748 | PubTator, text mining | PubMed |
| Germline mutations in Chinese ovarian cancer with or without breast cancer. | Mol Genet Genomic Med | 2022 | 35608067 | PubTator, text mining | PubMed |
| Clinician-Reported Impact of Germline Multigene Panel Testing on Cancer Risk Management Recommendations. | JNCI Cancer Spectr | 2022 | 35603838 | PubTator, text mining | PubMed |
| Apparent regional differences in the spectrum of BARD1 pathogenic variants in Spanish population and importance of copy number variants. | Sci Rep | 2022 | 35595798 | PubTator, text mining | PubMed |
| Distinct landscapes of deleterious variants in DNA damage repair system in ethnic human populations. | Life Sci Alliance | 2022 | 35595529 | PubTator, text mining | PubMed |
| Feasibility of whole genome and transcriptome profiling in pediatric and young adult cancers. | Nat Commun | 2022 | 35585047 | PubTator, text mining | PubMed |
| A bipartite graph-based expected networks approach identifies DDR genes not associated with TMB yet predictive of immune checkpoint blockade response. | Cell Rep Med | 2022 | 35584624 | PubTator, text mining | PubMed |
| Multifaceted regulation and functions of 53BP1 in NHEJ‑mediated DSB repair (Review). | Int J Mol Med | 2022 | 35583003 | PubTator, text mining | PubMed |
| The Bidirectional Link Between RNA Cleavage and Polyadenylation and Genome Stability: Recent Insights From a Systematic Screen. | Front Genet | 2022 | 35571036 | PubTator, text mining | PubMed |
| Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS. | Cancer Treat Res Commun | 2022 | 35567913 | PubTator, text mining | PubMed |
| A Novel Attention-Mechanism Based Cox Survival Model by Exploiting Pan-Cancer Empirical Genomic Information. | Cells | 2022 | 35563727 | PubTator, text mining | PubMed |
| MicroRNA-449a Inhibits Triple Negative Breast Cancer by Disturbing DNA Repair and Chromatid Separation. | Int J Mol Sci | 2022 | 35563522 | PubTator, text mining | PubMed |
| Beyond BRCA: The Emerging Significance of DNA Damage Response and Personalized Treatment in Pancreatic and Prostate Cancer Patients. | Int J Mol Sci | 2022 | 35563100 | PubTator, text mining | PubMed |
| A Community-Driven, Openly Accessible Molecular Pathway Integrating Knowledge on Malignant Pleural Mesothelioma. | Front Oncol | 2022 | 35558518 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/580/papers?page=55